Edgewise Therapeutics

Edgewise Therapeutics

EWTX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -7.1% in FY2025

Kevin Koch, Ph.D. is the CEO of Edgewise Therapeutics and was paid $7.4M in FY2025 (Dec), down 3%.

Pay$100 in the stock at the end of FY21 → $162
CEO pay is from each Edgewise Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives7

See all
  1. 1Kevin Koch, Ph.D.FY2025
  2. 2Robert Blaustein, M.D., Ph.D.FY2025
  3. 3Michael P. NofiFY2025
  4. 4Behrad Derakhshan, Ph.D.FY2025
  5. 5Joanne M. Donovan, M.D., Ph.D.FY2025
  6. 6Co-Founder andFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Edgewise Therapeutics paid its 7 named executives $27.3M in total in FY2025 (Dec). CEO Kevin Koch, Ph.D. was paid $7.4M of that.

Name
Kevin Koch, Ph.D.President and Chief Executive Officer
Robert Blaustein, M.D., Ph.D.Former Chief Development OfficerNot disclosedNot disclosed
Michael P. NofiChief Financial OfficerNot disclosedNot disclosed
Behrad Derakhshan, Ph.D.Chief Operating Officer
Joanne M. Donovan, M.D., Ph.D.Chief Medical Officer
Co-Founder andChief Scientific OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Edgewise Therapeutics names 20 peer companies for pay. Pay versus performance data of Edgewise Therapeutics for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board8

See all
  • Alan Russell, Ph.D.Director · 8 yr on the boardNot independent—Paid as an executive
  • Kevin Koch, Ph.D.Director · 8 yr on the boardNot independent—Paid as an executive
  • Jonathan RootDirector · 6 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
  • Jonathan FoxDirector · 2 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Arlene M. MorrisDirector · 1 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • Christopher MartinDirector · 0 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Board
    Christopher Martin joined the board of Edgewise Therapeutics. Christopher Martin sits on no other public board.
    3
  2. Pay
    Edgewise Therapeutics CEO pay rose 91% to $7.6M. The stock rose 144% in FY2024 (Dec).
    DEF 14A
  3. Pay
    Edgewise Therapeutics Division head pay rose 70% to $2.9M. The stock rose 144% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Edgewise Therapeutics COO pay rose 65% to $2.9M. The stock rose 144% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Edgewise Therapeutics CEO pay fell 26% to $4.0M. The stock rose 22% in FY2023 (Dec).
    DEF 14A
  6. Pay
    Edgewise Therapeutics Division head pay fell 38% to $1.7M. The stock rose 22% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Edgewise Therapeutics COO pay fell 22% to $1.8M. The stock rose 22% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 23, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 3, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 22, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data